Phase 3 Parkinson's Disease Trial, Recruiting NCT07216703 Sponsor: Merck Sharp & Dohme LLC Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 3 Parkinson's Disease Trial, Recruiting

NCT07216703
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a laboratory-confirmed diagnosis of one of three types of cervical cancer: squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma
  • People whose cervical cancer has persisted, come back after treatment, or has been newly diagnosed as having spread to distant parts of the body (advanced stage), and where surgery or radiation cannot cure it
  • People living with HIV, provided their HIV is well controlled with medication
  • People who have hepatitis B, provided they are on antiviral treatment and the virus is undetectable in their blood
  • People with a history of hepatitis C, provided the virus is undetectable in their blood
  • People whose general health and ability to carry out daily activities meets a specific standard (rated 0 or 1 on a medical scale, meaning fully active or able to carry out light activity) (confirm with trial site)
  • People whose tumor tests positive for a protein called PD-L1 at a certain level (combined positive score of 1 or higher) (confirm with trial site)

Who may not be able to join:

  • People living with HIV who have a history of a cancer called Kaposi's sarcoma or a condition called Multicentric Castleman's Disease
  • People with a history of serious dry eye syndrome, serious eyelid gland disease, serious eyelid inflammation, or serious corneal conditions that affect healing
  • People with active inflammatory bowel disease (such as Crohn's disease or ulcerative colitis) requiring immune-suppressing medication, or who have a history of these conditions or long-term diarrhoea
  • People with serious, uncontrolled heart or blood vessel disease, or serious brain and blood vessel disease
  • People who have previously received certain types of cancer treatment that fall outside what this trial allows (confirm with trial site)
  • People currently taking certain strong medications that affect how the body processes drugs, if those medications cannot be stopped during the trial (confirm with trial site)
  • People who have been diagnosed with an immune system deficiency condition
  • People who have another cancer that is still growing or has required active treatment within the past three years
  • People with active cancer that has spread to the brain or the lining around the brain and spinal cord
  • People with an active autoimmune disease that has needed medical treatment in the past two years (note: hormone or natural replacement therapies such as thyroid medication, insulin, or low-dose steroids may still be acceptable)
  • People with a history of non-infectious lung inflammation that needed steroid treatment, or who currently have or are suspected to have lung inflammation that cannot be ruled out
  • People who have previously had a stem cell or solid organ transplant
  • People who have not fully recovered from major surgery, or who are still experiencing complications from surgery

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Medical Director, Merck Sharp & Dohme LLC

Phone: 1-888-577-8839

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
19 January 2026
Est. completion
29 October 2031

Where this trial is recruiting

🇦🇷 Argentina 🇦🇹 Austria 🇧🇪 Belgium 🇧🇷 Brazil 🇨🇦 Canada 🇨🇱 Chile 🇨🇴 Colombia 🇨🇿 Czechia 🇫🇷 France 🇬🇷 Greece 🇭🇺 Hungary 🇮🇳 India 🇮🇪 Ireland 🇮🇱 Israel 🇮🇹 Italy 🇯🇵 Japan 🇲🇽 Mexico 🇵🇱 Poland 🇿🇦 South Africa 🇰🇷 South Korea 🇪🇸 Spain 🇸🇪 Sweden 🇹🇼 Taiwan 🇹🇭 Thailand 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Part 1 Safety Run-in: Number of Participants Who Experience One or More Adverse Events (AEs); Part 1 Safety Run-in: Number of Participants Who Discontinue Study Treatment Due to an AE; Part 2 Maintenance Treatment: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR); Part 2 Maintenance Treatment: Overall Survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov